The present study uncovers a mutant IDH‐specific metabolic landscape which is clinically relevant and highlights novel metabolic vulnerabilities in IDH‐mutant gliomas that may be therapeutically exploited. The gene discussed is IDH2; the disease is central nervous system cancer.